According to an average estimate of four brokerages, revenue from operations in the January-March 2023 period is seen growing up to 18% year-on-year. Meanwhile, net profit after tax is likely to surge up to 54% YoY.
While earnings for Dr Reddy s is expected to remain strong in Q4, an uptick in R&D investments and new intitative may cap the drugmaker s margin expansion.